Single Daily Busulfan Dosing for Infants with Nonmalignant Diseases Undergoing Reduced-Intensity Conditioning for Allogeneic Hematopoietic Progenitor Cell Transplantation

Biology of Blood and Marrow Transplantation

Volumn 21, Issue 9, 2015, Pages 1612-1621

  Ward, Jessica ^a   Kletzel, Morris ^a   Duerst, Reggie ^a   Fuleihan, Ramsay ^a   Chaudhury, Sonali ^a   Schneiderman, Jennifer ^a   Tse, William T ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Busulfan fludarabine; Hematopoietic progenitor cell transplantation; Infants; Pediatrics; Pharmacokinetics; Single dose daily regimen

Indexed keywords

ACICLOVIR; BUSULFAN; CYCLOSPORIN A; FLUDARABINE; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; LORAZEPAM; MYCOPHENOLATE MOFETIL; PENTAMIDINE; THIOTEPA; THYMOCYTE ANTIBODY;

ALBERS SCHOENBERG DISEASE; ANTIVIRAL THERAPY; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; COHORT ANALYSIS; DRUG CLEARANCE; FEMALE; GAUCHER DISEASE; GLOBOID CELL LEUKODYSTROPHY; GRAFT FAILURE; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFANT; INFANT DISEASE; IPEX SYNDROME; MAJOR HISTOCOMPATIBILITY COMPLEX II DEFICIENCY; MALE; MORBIDITY; NEMO SYNDROME; OMENN SYNDROME; OUTCOME ASSESSMENT; OVERALL SURVIVAL; REDUCED INTENSITY CONDITIONING; SINGLE DRUG DOSE; WISKOTT ALDRICH SYNDROME; ALLOGRAFT; CLINICAL TRIAL; CORD BLOOD STEM CELL TRANSPLANTATION; DISEASE FREE SURVIVAL; FOLLOW UP; NEWBORN; SURVIVAL RATE; TRANSPLANTATION CONDITIONING;

ALLOGRAFTS; BUSULFAN; CORD BLOOD STEM CELL TRANSPLANTATION; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFANT; INFANT, NEWBORN; MALE; SURVIVAL RATE; TRANSPLANTATION CONDITIONING;

EID: 84938982583     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2015.05.017     Document Type: Article

References (51)

1. Smedler A.C., Bolme P. Neuropsychological deficits in very young bone marrow transplant recipients. Acta Paediatr 1995, 84:429-433.
2. Leung W., Hudson M., Zhu Y., et al. Late effects in survivors of infant leukemia. Leukemia 2000, 14:1185-1190.
3. Jacobsohn D.A., Duerst R., Tse W., Kletzel M. Reduced intensity haemopoietic stem-cell transplantation for treatment of non-malignant diseases in children. Lancet 2004, 364:156-162.
4. Tse W.T., Duerst R., Schneiderman J., et al. Age-dependent pharmacokinetic profile of single daily dose i.v. busulfan in children undergoing reduced-intensity conditioning stem cell transplant. Bone Marrow Transplant 2009, 44:145-156.
5. Dix S.P., Wingard J.R., Mullins R.E., et al. Association of busulfan area under the curve with veno-occlusive disease following BMT. Bone Marrow Transplant 1996, 17:225-230.
6. Lindley C., Shea T., McCune J., et al. Intraindividual variability in busulfan pharmacokinetics in patients undergoing a bone marrow transplant: assessment of a test dose and first dose strategy. Anticancer Drugs 2004, 15:453-459.
7. Bolinger A.M., Zangwill A.B., Slattery J.T., et al. Target dose adjustment of busulfan in pediatric patients undergoing bone marrow transplantation. Bone Marrow Transplant 2001, 28:1013-1018.
8. Grochow L.B. Busulfan disposition: the role of therapeutic monitoring in bone marrow transplantation induction regimens. Semin Oncol 1993, 20:18-25.
9. Hassan M., Ljungman P., Bolme P., et al. Busulfan bioavailability. Blood 1994, 84:2144-2150.
10. Wall D.A., Chan K.W., Nieder M.L., et al. Safety, efficacy, and pharmacokinetics of intravenous busulfan in children undergoing allogeneic hematopoietic stem cell transplantation. Pediatr Blood Cancer 2010, 54:291-298.
11. Andersson B.S., Madden T., Tran H.T., et al. Acute safety and pharmacokinetics of intravenous busulfan when used with oral busulfan and cyclophosphamide as pretransplantation conditioning therapy: a phase I study. Biol Blood Marrow Transplant 2000, 6:548-554.
12. Fernandez H.F., Tran H.T., Albrecht F., et al. Evaluation of safety and pharmacokinetics of administering intravenous busulfan in a twice-daily or daily schedule to patients with advanced hematologic malignant disease undergoing stem cell transplantation. Biol Blood Marrow Transplant 2002, 8:486-492.
13. Russell J.A., Tran H.T., Quinlan D., et al. Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. Biol Blood Marrow Transplant 2002, 8:468-476.
14. Kletzel M., Jacobsohn D., Duerst R. Pharmacokinetics of a test dose of intravenous busulfan guide dose modifications to achieve an optimal area under the curve of a single daily dose of intravenous busulfan in children undergoing a reduced-intensity conditioning regimen with hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2006, 12:472-479.
15. Andersson B.S., Thall P.F., Madden T., et al. Busulfan systemic exposure relative to regimen-related toxicity and acute graft-versus-host disease: defining a therapeutic window for i.v. BuCy2 in chronic myelogenous leukemia. Biol Blood Marrow Transplant 2002, 8:477-485.
16. Wagner J.E., Barker J.N., DeFor T.E., et al. Transplantation of unrelated donor umbilical cord blood in 102 patients with malignant and nonmalignant diseases: influence of CD34 cell dose and HLA disparity on treatment-related mortality and survival. Blood 2002, 100:1611-1618.
17. Vassal G., Koscielny S., Challine D., et al. Busulfan disposition and hepatic veno-occlusive disease in children undergoing bone marrow transplantation. Cancer Chemother Pharmacol 1996, 37:247-253.
18. Shaw P.J., Scharping C.E., Brian R.J., Earl J.W. Busulfan pharmacokinetics using a single daily high-dose regimen in children with acute leukemia. Blood 1994, 84:2357-2362.
19. Andersson B.S., de Lima M., Thall P.F., et al. Once daily i.v. busulfan and fludarabine (i.v. Bu-Flu) compares favorably with i.v. busulfan and cyclophosphamide (i.v. BuCy2) as pretransplant conditioning therapy in AML/MDS. Biol Blood Marrow Transplant 2008, 14:672-684.
20. Olavarria E., Hassan M., Eades A., et al. A phase I/II study of multiple-dose intravenous busulfan as myeloablation prior to stem cell transplantation. Leukemia 2000, 14:1954-1959.
21. Vassal G., Michel G., Esperou H., et al. Prospective validation of a novel IV busulfan fixed dosing for paediatric patients to improve therapeutic AUC targeting without drug monitoring. Cancer Chemother Pharmacol 2008, 61:113-123.
22. Dupuis L.L., Sibbald C., Schechter T., et al. IV busulfan dose individualization in children undergoing hematopoietic stem cell transplant: limited sampling strategies. Biol Blood Marrow Transplant 2008, 14:576-582.
23. McCune J.S., Baker K.S., Blough D.K., et al. Variation in prescribing patterns and therapeutic drug monitoring of intravenous busulfan in pediatric hematopoietic cell transplant recipients. J Clin Pharmacol 2013, 53:264-275.
24. Grochow L.B., Krivit W., Whitley C.B., Blazar B. Busulfan disposition in children. Blood 1990, 75:1723-1727.
25. Hassan M., Fasth A., Gerritsen B., et al. Busulphan kinetics and limited sampling model in children with leukemia and inherited disorders. Bone Marrow Transplant 1996, 18:843-850.
26. Kim A.H., Tse J.C., Ikeda A., Moore T.B. Evaluating pharmacokinetics and pharmacodynamics of intravenous busulfan in pediatric patients receiving bone marrow transplantation. Pediatr Transplant 2009, 13:971-976.
27. Savic R.M., Cowan M.J., Dvorak C.C., et al. Effect of weight and maturation on busulfan clearance in infants and small children undergoing hematopoietic cell transplantation. Biol Blood Marrow Transplant 2013, 19:1608-1614.
28. Dalle J.H., Wall D., Theoret Y., et al. Intravenous busulfan for allogeneic hematopoietic stem cell transplantation in infants: clinical and pharmacokinetic results. Bone Marrow Transplant 2003, 32:647-651.
29. Zwaveling J., Bredius R.G., Cremers S.C., et al. Intravenous busulfan in children prior to stem cell transplantation: study of pharmacokinetics in association with early clinical outcome and toxicity. Bone Marrow Transplant 2005, 35:17-23.
30. Hassan M., Oberg G., Bekassy A.N., et al. Pharmacokinetics of high-dose busulphan in relation to age and chronopharmacology. Cancer Chemother Pharmacol 1991, 28:130-134.
31. Hassan M., Nilsson C., Hassan Z., et al. A phase II trial of liposomal busulphan as an intravenous myeloablative agent prior to stem cell transplantation: 500 mg/m(2) as a optimal total dose for conditioning. Bone Marrow Transplant 2002, 30:833-841.
32. Paci A., Vassal G., Moshous D., et al. Pharmacokinetic behavior and appraisal of intravenous busulfan dosing in infants and older children: the results of a population pharmacokinetic study from a large pediatric cohort undergoing hematopoietic stem-cell transplantation. Ther Drug Monit 2012, 34:198-208.
33. Schechter T., Finkelstein Y., Doyle J., et al. Pharmacokinetic disposition and clinical outcomes in infants and children receiving intravenous busulfan for allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2007, 13:307-314.
34. Slattery J.T., Sanders J.E., Buckner C.D., et al. Graft-rejection and toxicity following bone marrow transplantation in relation to busulfan pharmacokinetics. Bone Marrow Transplant 1995, 16:31-42.
35. Copelan E.A., Bechtel T.P., Avalos B.R., et al. Busulfan levels are influenced by prior treatment and are associated with hepatic veno-occlusive disease and early mortality but not with delayed complications following marrow transplantation. Bone Marrow Transplant 2001, 27:1121-1124.
36. Kerl K., Diestelhorst C., Bartelink I., et al. Evaluation of effects of busulfan and DMA on SOS in pediatric stem cell recipients. Pediatr Blood Cancer 2014, 61:306-311.
37. Gokce M., Kuskonmaz B., Cetin M., et al. Coexisting or underlying risk factors of hepatic veno-occlusive disease in pediatric hematopoietic stem cell transplant recipients receiving prophylaxis. Exp Clin Transplant 2013, 11:440-446.
38. McPherson M.E., Hutcherson D., Olson E., et al. Safety and efficacy of targeted busulfan therapy in children undergoing myeloablative matched sibling donor BMT for sickle cell disease. Bone Marrow Transplant 2011, 46:27-33.
39. Michel G., Valteau-Couanet D., Gentet J.C., et al. Weight-based strategy of dose administration in children using intravenous busulfan: clinical and pharmacokinetic results. Pediatr Blood Cancer 2012, 58:90-97.
40. Caselli D., Rosati A., Faraci M., et al. Risk of seizures in children receiving busulphan-containing regimens for stem cell transplantation. Biol Blood Marrow Transplant 2014, 20:282-285.
41. Hussein A.A., Hamadah T., Domm J., et al. Allogeneic hematopoietic stem cell transplantation for infants with idiopathic myelofibrosis. Pediatr Transplant 2013, 17:815-819.
42. Ferrara J.L., Levine J.E., Reddy P., Holler E. Graft-versus-host disease. Lancet 2009, 373:1550-1561.
43. Lee J.H., Joo Y.D., Kim H., et al. Randomized trial of myeloablative conditioning regimens: busulfan plus cyclophosphamide versus busulfan plus fludarabine. J Clin Oncol 2013, 31:701-709.
44. Horn B., Baxter-Lowe L.A., Englert L., et al. Reduced intensity conditioning using intravenous busulfan, fludarabine and rabbit ATG for children with nonmalignant disorders and CML. Bone Marrow Transplant 2006, 37:263-269.
45. Bartelink I.H., van Reij E.M., Gerhardt C.E., et al. Fludarabine and exposure-targeted busulfan compares favorably with busulfan/cyclophosphamide-based regimens in pediatric hematopoietic cell transplantation: maintaining efficacy with less toxicity. Biol Blood Marrow Transplant 2014, 20:345-353.
46. Bartelink I.H., Bredius R.G., Belitser S.V., et al. Association between busulfan exposure and outcome in children receiving intravenous busulfan before hematologic stem cell transplantation. Biol Blood Marrow Transplant 2009, 15:231-241.
47. Law J., Cowan M.J., Dvorak C.C., et al. Busulfan, fludarabine, and alemtuzumab as a reduced toxicity regimen for children with malignant and nonmalignant diseases improves engraftment and graft-versus-host disease without delaying immune reconstitution. Biol Blood Marrow Transplant 2012, 18:1656-1663.
48. Horwitz M.E., Morris A., Gasparetto C., et al. Myeloablative intravenous busulfan/fludarabine conditioning does not facilitate reliable engraftment of dual umbilical cord blood grafts in adult recipients. Biol Blood Marrow Transplant 2008, 14:591-594.
49. Ansari M., Theoret Y., Rezgui M.A., et al. Association between busulfan exposure and outcome in children receiving intravenous busulfan before hematopoietic stem cell transplantation. Ther Drug Monit 2014, 36:93-99.
50. Kamani N.R., Walters M.C., Carter S., et al. Unrelated donor cord blood transplantation for children with severe sickle cell disease: results of one cohort from the phase II study from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN). Biol Blood Marrow Transplant 2012, 18:1265-1272.
51. Radhakrishnan K., Bhatia M., Geyer M.B., et al. Busulfan, fludarabine, and alemtuzumab conditioning and unrelated cord blood transplantation in children with sickle cell disease. Biol Blood Marrow Transplant 2013, 19:676-677.